Transcriptomic study of dormant gastrointestinal cancer stem cells

Area of Science:

• Gastrointestinal cancer research
• Cancer stem cell biology
• Epigenetics and molecular oncology

Background:

• Cancer stem cells (CSCs) in gastrointestinal cancer exist in dormant and proliferating states.
• This coexistence contributes to chemoradiation resistance and tumor relapse.
• Dormant CSCs (CD13+/CD90-) survive hypoxic conditions and exhibit limited proliferation, while proliferating CSCs (CD13-/CD90+) are chemo-sensitive.

Purpose of the Study:

• To investigate the epigenetic mechanisms driving the malignant behavior of dormant CSCs.
• To understand how dormancy contributes to therapy resistance and cancer progression.
• To identify potential molecular targets for novel cancer therapies.

Main Methods:

• Transcriptomic analysis to elucidate epigenetic regulation in dormant CSCs.
• Investigation of DNA repair mechanisms (non-homologous end-joining vs. homologous recombination) in different CSC populations.
• Analysis of signaling pathways including EZH2, TP53, and microRNA101.

Main Results:

• Dormant CSCs (CD13+) predominantly utilize error-prone non-homologous end-joining for DNA repair after damage.
• Proliferating CSCs (CD13-) show high-fidelity homologous recombination.
• Transcriptomic studies revealed simultaneous activation of EZH2- and TP53-related pathways in dormant CSCs, regulated by microRNA101.

Conclusions:

• Dormancy is a critical protective mechanism for CSCs against therapy.
• Epigenetic dysregulation, specifically involving microRNA101, EZH2, and TP53, underlies the malignant behavior of dormant CSCs.
• A pharmacogenomic approach targeting these pathways holds promise for developing novel molecular therapies against gastrointestinal cancer.